Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Dec 25, 2023; 12(5): 182-200
Published online Dec 25, 2023. doi: 10.5527/wjn.v12.i5.182
Published online Dec 25, 2023. doi: 10.5527/wjn.v12.i5.182
Heterogeneity in cardiorenal protection by Sodium glucose cotransporter 2 inhibitors in heart failure across the ejection fraction strata: Systematic review and meta-analysis
Saeed Taheri, Department of Medicine, New Lahijan Scientific Foundation, Lahijan 4415813166, Iran
Author contributions: Taheri S performed all the tasks.
Conflict-of-interest statement: No financial support was received by the author. The author has no financial interests on the findings of this study.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Saeed Taheri, MD, Doctor, Department of Medicine, New Lahijan Scientific Foundation, #1 Kargar 19, 2nd ave; Lahijan; Iran , Lahijan 4415813166, Iran. taherimd@gmail.com
Received: May 23, 2023
Peer-review started: May 23, 2023
First decision: August 16, 2023
Revised: September 1, 2023
Accepted: September 25, 2023
Article in press: September 25, 2023
Published online: December 25, 2023
Peer-review started: May 23, 2023
First decision: August 16, 2023
Revised: September 1, 2023
Accepted: September 25, 2023
Article in press: September 25, 2023
Published online: December 25, 2023
Core Tip
Core Tip: Compared to placebo, treatment with Sodium glucose cotransporter 2 inhibitors improve cardiorenal outcomes in a broad range of disorders with significant heterogeneity in the subgroup of patients who are likely to benefit most from the treatment across their heart failure subtypes, New York Heart Associations classifications and ejection fraction levels. There are also adverse events associated with these drugs that deserve further research.